Compare iShares Semiconductor ETF (SOXX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Zoetis Inc — how do they compare? iShares Semiconductor ETF trades at $551.5, while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while iShares Semiconductor ETF pays none, and iShares Semiconductor ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SOXX | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $156.76 |
52-Week Low | $236.93 | $71.91 |
Market Cap | — | $31.95B |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $524.14, up 0.45% with a bearish technical signal from moving averages. The semiconductor ETF faces volatility amid AI sector rotation, with RSI levels below 30 suggesting potential oversold conditions. Recent news highlights semiconductor leadership in market rebounds but also bear market concerns, with the ETF down 20% from June highs. Support levels cluster around $518-$512, while resistance begins at $529.
Outlook remains cautious due to sector concentration risks and cyclical pressures, though oversold technicals may offer near-term bounce potential. Key risks include AI trade volatility, China export controls, and hyperscaler capex pressures. Analyst views are mixed, with some highlighting long-term growth prospects despite recent underperformance.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
